首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors.
【24h】

Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors.

机译:对小型肺或肝肿瘤三维共形超分割大剂量放射治疗与肿瘤控制可能性相关因素的单因素分析。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To show the factors correlated with tumor control probability (TCP) after three-dimensional conformal hypofractionated high-dose radiotherapy (3D-CHHRT) for small pulmonary or hepatic tumors. METHODS AND MATERIALS: We enrolled 34 patients with 42 lesions (13 lung carcinomas, 6 hepatocellular carcinomas, and 23 lung or liver metastases) treated with 3D-CHHRT alone, with simple immobilization devices, between July 1997 and January 2002. We prescribed 45 Gy in three fractions at the 90-100% isodose line of the planning target volume. The median follow-up period was 18 months (range, 4-46 months). We calculated the TCP using the Kaplan-Meier method and univariate analysis for the following factors: age, gender, primary site, histologic type, tumor size, and previous treatment. RESULTS: Overall, the 2-year TCP of 3D-CHHRT was 83.6%. Local recurrence was observed in 6 lesions within 1 year after treatment. We showed that tumor size was the only significant factor to correlate with the TCP in univariate analysis. The 2-year TCP for tumors <3 cm or >/=3 cm in diameter was 95.0% and 58.3%, respectively (p = 0.0022). No severe adverse effects were observed. CONCLUSION: The TCP for tumors <3 cm in diameter was excellent for 3D-CHHRT.
机译:目的:显示与3D-CHHRT三维共形超分割大剂量放射治疗后的小肺或肝肿瘤相关的因素。方法和材料:1997年7月至2002年1月,我们采用简单的固定装置对34例有42处病变(13例肺癌,6例肝细胞癌以及23例肺或肝转移)的患者进行了单独3D-CHHRT治疗。计划目标量的90-100%等剂量线分为三部分。中位随访期为18个月(范围4-46个月)。我们使用Kaplan-Meier方法和单因素分析计算了以下因素的TCP:年龄,性别,原发部位,组织学类型,肿瘤大小和以前的治疗。结果:总体而言,3D-CHHRT的2年TCP为83.6%。治疗后1年内在6个病变中观察到局部复发。我们显示肿瘤大小是单因素分析中与TCP相关的唯一重要因素。直径<3 cm或> / = 3 cm的肿瘤的2年TCP分别为95.0%和58.3%(p = 0.0022)。没有观察到严重的不良反应。结论:对于直径<3 cm的肿瘤,TCP对于3D-CHHRT非常有效。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号